People: Tissue Therapies Ltd (TIS.AX)

TIS.AX on Australia Stock Exchange

0.04AUD
7 Jul 2015
Change (% chg)

$-0.00 (-2.78%)
Prev Close
$0.04
Open
$0.04
Day's High
$0.04
Day's Low
$0.03
Volume
351,980
Avg. Vol
571,019
52-wk High
$0.46
52-wk Low
$0.03

Search Stocks

Summary

Name Age Since Current Position

Nigel Johnson

2015 Acting Chief Executive Officer

Drummond McKenzie

Chief Financial Officer, Company Secretary

Zee Upton

Chief Scientific Officer

Melvyn Bridges

2009 Non-Executive Director

Cherrell Hirst

2009 Non-Executive Director

Timothy Hughes

2014 Non-Executive Director

Iain Ross

61 2012 Non-Executive Director

Biographies

Name Description

Nigel Johnson

Mr. Nigel Johnson has been appointed as Acting Chief Executive Officer of Tissue Therapies Ltd., with effect from 7 April 2015. He has more than 17 years experience in the medical device and biologics industries, principally with responsibilities for development, manufacturing, quality management and regulatory affairs in Europe, Australia, Canada and the United States. He has been instrumental in the development and manufacturing of VitroGro ECM for commercial sale. He holds a Bachelor of Applied Science.

Drummond McKenzie

Mr. Drummond McKenzie is Chief Financial Officer and Company Secretary of Tissue Therapies Ltd. Mr. McKenzie holds Bachelor of Science (Economics) (Hons.) Fellow of the Institute of Chartered Accountants Fellow of the Institute of Chartered Secretaries.He has over 15 years experience in the financial management and administration of public companies.

Zee Upton

Ms. Zee Upton is Chief Scientific Officer of Tissue Therapies Ltd. Prof. Upton is VitroGro and oversees the Company's research activities as its Consulting Chief Scientific Officer. Prof. Upton is an biochemist and tissue engineer. She is Assistant Dean (Research) in the Faculty of Health, QUT and Leader of the Tissue Repair and Regeneration Program within the QUT Institute of Health and Biomedical Innovation.

Melvyn Bridges

Dr. Melvyn (Mel) John Bridges has been Non-Executive Director of Tissue Therapies Ltd since March 12, 2009. He holds a Bachelor of Science (Chemistry) and is Fellow of the Australian Institute of Company Directors. He has experience as a CEO and Company Director in healthcare, agricultural technology, drug development, pathology, diagnostics and medical devices. Related experience in retail. Has successfully raised in excess of $300 million investment capital in the healthcare/biotech sector and been directly involved in over $1 billion in M&A and related transactions. Director of ALS Limited (formerly Campbell Brothers Limited).

Cherrell Hirst

Dr. Cherrell Hirst has been Non-Executive Director of Tissue Therapies Ltd since June 30, 2009. She holds a Bachelor of Medicine, Bachelor of Surgery, Bachelor of Education Studies Honorary Doctorates from Queensland University of Technology, Griffith University and Southern Cross University Fellow of the Australian Institute of Company Directors Fellow of the Academy of Technological Sciences and Engineering.She has experience as Chairman of ImpediMed Limited and Director of Medibank Private Limited, Verva Pharmaceuticals Limited and the Gold Coast Hospital and Health Service Distinguished clinical career in the detection and treatment of breast cancer and extensive and respected achievements as Director and Chair of multiple commercial, government and not-for-profit organisations.

Timothy Hughes

Mr. Timothy Richard Hughes is Non-Executive Director of the Company. Mr. Hughes, who is based in Sydney, has significant experience in investment banking and finance from the senior positions he has held with Rothschilds Australia and within the superannuation industry and his experience as a director of various companies including Alchemia Ltd, Value Capital Management Pty Ltd and South Endeavour Pty Ltd.

Iain Ross

Mr. Iain Gladstone Ross has been Non-Executive Director of Tissue Therapies Ltd since May 25, 2012. He holds a Bachelor of Science in Biochemistry from the University of London.He has experience as Chairman of Ark Therapeutics Plc (LSE), Biomer Technology Limited and Pharminox Limited, Director of Benitec BioPharma Limited, Novogen Limited, Anatara Lifesciences Limited and Yellow Cross Limited. Mr Ross is also a Vice Chairman and Trustee of Royal Holloway, London University.

Basic Compensation

Name Fiscal Year Total

Nigel Johnson

--

Drummond McKenzie

214,345

Zee Upton

--

Melvyn Bridges

59,952

Cherrell Hirst

59,950

Timothy Hughes

--

Iain Ross

59,750
As Of  29 Jun 2014

Options Compensation

Search Stocks